Significance of mouse xenograft tumor model using patient-derived cancer organoids for clinical drug development.

ABSTRACT:

Background

In vitro and in vivo preclinical examinations of cancer cell lines are performed to determine the effectiveness of new drugs before initiating clinical trials. However, there is often a significant disparity between the promising results observed in preclinical evaluations and actual outcomes in clinical trials. Therefore, we hypothesized that this inconsistency might be due to the differences between the characteristics of cell lines and actual cancers in patients. Therefore, we screened drugs for bile duct cancer to test our hypotheses.

Methods

We established patient-derived cancer organoids (PDCOs) from the surgical samples of patients with bile duct cancer and conducted multiple in vitro drug screening tests.

Results

We identified p

SUBMITTER: Ogawa H 

PROVIDER: S-EPMC11896854 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature